Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jaimin Shah

Neurology Jacksonville, FL Medical Doctor

NPI 1518285782 CMS profile 1396451

4500 San Pablo Rd S, Jacksonville, FL 32224

Open in the dashboard

General payments

$731

14 records reported · program years 2019–2025

Research payments

$574

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$146,367 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Jaimin Shah of Jacksonville, FL is reported in the CMS Open Payments database as having received $731 across 14 general payments and $574 in research payments paid to them. Separately, studies naming them as principal investigator received $146,367 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 48th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $280 2
2024 General $29 1
2023 General $215 3
2022 General $30 1
2020 General $19 1
2019 General $158 6
2019 Research $574 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaimin Shah
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jaimin Shah were reported at $280. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jaimin Shah Neurology median Middle half National median
2019 $158 $474 $118–$2,177 $163
2020 $19 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $30 $442 $103–$2,388 $149
2023 $215 $464 $119–$2,312 $160
2024 $29 $468 $119–$2,323 $164
2025 $280 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $264 2 payments
  2. Cadwell Industries, INC $158 1 payment
  3. EMD Serono, Inc. $71 1 payment
  4. Alexion Pharmaceuticals, Inc. $50 1 payment
  5. Janssen Biotech, Inc. $40 2 payments
  6. Retrophin, Inc. $39 2 payments
  7. Hollister Incorporated $30 1 payment
  8. Coloplast Corp $29 1 payment
  9. Progenics Pharmaceuticals, Inc. $23 1 payment
  10. Baxter Healthcare $15 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $681 13 payments
  2. Education $50 1 payment
Products named General payments · program years 2019–2025
  1. RED 72 $142 1 payment
  2. Indigo System $122 1 payment
  3. ULTOMIRIS $50 1 payment
  4. ERLEADA $40 2 payments
  5. (815) Thiola $39 2 payments
  6. Infyna Chic $30 1 payment
  7. VaPro $30 1 payment
  8. Titan $29 1 payment
  9. PYLARIFY $23 1 payment
  10. TISSEEL $15 1 payment
  11. Other $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biogen, Inc. $574 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

288

Median for Neurology: 833

Drug cost

$1,366,953

Median for Neurology: $202,670

Branded share of claims

49.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 46 $609,961
Evrysdi Risdiplam Brand 17 $438,681
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 15 $145,633
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 13 $90,126
Nuedexta Dextromethorphan Hbr/Quinidine Brand 21 $57,805
Riluzole Generic 82 $22,358
Mycophenolate Mofetil Generic 19 $1,331
Methotrexate Methotrexate Sodium Brand 20 $467
Gabapentin Generic 29 $230
Atropine Sulfate Generic 15 $227

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$120,295

Medicare's payments for the services billed

Medicare patients

538

Average age 72

Services billed

1,518

271 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 37%
Diabetes 31%
Depression 30%
Chronic kidney disease 27%
Cancer 21%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record